N/A N=30 Collaboration Live
Pregnancy Related
Primary: Rate of Clinically Acceptable Performance of Remote Control Functionality — 100 Percentage of total exams
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 Study of Nivolumab for Advanced Cancers in India
Non-Small Cell Lung Cancer (NSCLC) · Non-Small-Cell Lung Carcinoma · Nonsmall Cell Lung Cancer
Primary: Number of Participants With Treatment-related Adverse Events — 25; 4; 1 Count of participants
Phase 3 N=1,060 Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment
Breast Neoplasms
Primary: Disease-free Survival (DFS) Events — 127; 112 events
N/A N=857 A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2
Smoking
Primary: Levels of High Density Lipoprotein C (HDL-C). — 52.2; 50.6; 54.0; 54.7 mg/dL
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
N/A N=20 Radio Frequency Microneedling for Suprapatellar Skin
Skin Laxity
Primary: Photographic Knee Laxity and Texture Evaluation — 1.87; 2.02 score on a scale
N/A N=139 Brief Behavioral Intervention for Insomnia During Chemotherapy
Breast Cancer · Insomnia
Primary: Insomnia Severity Index (ISI) — 13.73; 14.93; 11.28; 10.16 score on a scale
N/A N=30 Play Intervention for Dementia for Promoting Cognitive Function: A Feasibility Study
Dementia · Alzheimer Disease
Primary: Adjusted Post-test Score of Montreal Cognitive Assessment Scale After 2 Months of Intervention — 8.84; 7.40 score on a scale
N/A N=81 Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19
Infections, Coronavirus
Primary: Clinical Status of the Patient (According to 7-point Ordinal Scale) — 0; 0; 22; 24 Participants — p=<0.0000001
N/A N=6 BreEStim and tDCS for Neuropathic Pain Management - Healthy Subjects
Pain Management
Primary: Electrical Pain Threshold (EPT) — 23.83; 22.41; 24.08; 20.41 mA
Phase 3 N=915 Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15) — -0.4049; -0.1574 score on a scale
Phase 2 N=395 Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) — 84.6; 85.0; 92.5; 88.6 percentage of participants
Phase 2 N=5 MMF for HIV Reservoir Reduction
Human Immunodeficiency Virus I Infection
Primary: Change in Cell-associated HIV DNA (Ca-DNA) Levels Per 10^6 T Cells Over 12 Months — -0.00033 log10 caDNA copies per 10^6 T-cells/week
Phase 2 N=120 To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin
Androgenic Alopecia
Primary: Scalp Hair Density — 1.46; 2.58; -4.10; 6.68 Change from baseline (No. of hairs/cm2)
Phase 2 N=45 Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse
Dental Plaque · Dental Caries
Primary: Composite Plaque Score — 36.2; 37.9 score on a scale — p=.044